de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Information

    1. Events
    2. Information Request
  • Products

    Remimazolam

    1. About Remimazolam
    2. UK SMPC for remimazolam
    3. UK PIL for remimazolam

    Angiotensin II

    1. About Angiotensin II

    Eravacycline

    1. About eravacycline
  • Career

    What does PAIONeering mean to us?

    What PAIONeers can expect

    1. Professional Development

    Job offers

  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board

    Annual general meeting

    2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
  • Contact

    Germany

    UK

    Nordic Countries

    Netherlands

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2013
  • 12/17/2013

    PAION AG to issue approx. 2.8 million shares at EUR 1.80 per share in capital increase with subscription rights

    • PDF

  • 11/26/2013

    PAION grants licence for Turkey to add to R-Pharm territory

    • PDF

  • 11/25/2013

    PAION AG announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation

    • PDF

  • 11/14/2013

    PAION AG reports headline data of ONO's phase II/III trial - Remimazolam meets primary endpoint and shows good safety data

    • PDF

  • 10/30/2013

    PAION AG grants license to R-Pharm for Remimazolam in Russia (CIS)

    • PDF

  • 10/30/2013

    PAION AG announced recruitment of Ono's hepatic impairment study with Remimazolam (development codes: ONO-2745/CNS 7056) is completed

    • PDF

  • 10/28/2013

    PAION AG grants license to Hana Pharm for Remimazolam in South Korea

    • PDF

  • 09/09/2013

    PAION starts Phase II study with Remimazolam in the indication anaesthesia

    • PDF

  • 08/07/2013

    PAION AG reports financial results for the first half year 2013

    • PDF

  • 08/05/2013

    PAION AG: German regulatory authority approved Phase II study of Remimazolam in indication anaesthesia

    • PDF

  • 08/01/2013

    PAION's partner ONO stopped its dose finding, explorative Phase II trial in ICU sedation with Remimazolam and plans to adapt the dose regime for a new study

    • PDF

  • 07/02/2013

    PAION signs exclusive option agreement with Hana Pharm for Remimazolam in South Korea

    • PDF

  • 05/08/2013

    Recruitment of Phase II/III Study with short-acting anaesthetic/sedative Remimazolam (ONO's Development code: ONO-2745) in Japan is completed

    • PDF

  • 05/07/2013

    PAION receives Milestone of GBP 300,000 after Cambridge Cognition Holdings Lists on London Stock Exchange

    • PDF

  • 03/13/2013

    PAION AG reports financial results for the full year 2012

    • PDF

  • 03/06/2013

    PAION announces clinical development of short-acting anaesthetic/sedative Remimazolam in General Anaesthesia

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Heussstraße 25 | 52078 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Information +
    1. Events
    2. Information Request
Products
  1. Remimazolam +
    1. About Remimazolam
    2. UK SMPC for remimazolam
    3. UK PIL for remimazolam
  2. Angiotensin II +
    1. About Angiotensin II
  3. Eravacycline +
    1. About eravacycline
Career
  1. What does PAIONeering mean to us?
  2. What PAIONeers can expect +
    1. Professional Development
  3. Job offers
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board
  6. Annual general meeting +
    1. 2022
    2. 2021
    3. 2020
    4. 2019
    5. 2018
    6. 2017
    7. 2016
    8. 2015
    9. 2014
    10. 2013
    11. 2012
    12. 2011
Contact
  1. Germany
  2. UK
  3. Nordic Countries
  4. Netherlands
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint